2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
Lambertini M, Ceppi M, Anderson R, Cameron D, Bruzzone M, Franzoi M, Massarotti C, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn J, Latocca M, Arecco L, Pistilli B, Ruddy K, Ballestrero A, Del Mastro L, Peccatori F, Partridge A, Saura C, Untch M, Piccart M, Di Cosimo S, de Azambuja E, Demeestere I. Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer. Journal Of The National Comprehensive Cancer Network 2023, 21: 33-41.e16. PMID: 36634607, DOI: 10.6004/jnccn.2022.7065.Peer-Reviewed Original ResearchConceptsAnti-HER2 therapyAMH levelsOvarian reserveWeekly paclitaxelAntimüllerian hormoneBreast cancerWeek 2HER2-positive early breast cancerHER2-positive breast cancerSubsequent ovarian functionAnti-HER2 agentsAnti-HER2 treatmentMedian AMH levelsEarly breast cancerTime of surgeryFrozen serum samplesBiomarker analysisNeoALTTO trialPotential gonadotoxicityPremenopausal womenMedian ageAMH valuesOvarian functionAMH declineGonadotoxicity
2022
Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial.
Lambertini M, Ceppi M, Anderson R, Cameron D, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn J, Arecco L, Del Mastro L, Partridge A, Saura C, Untch M, Piccart-Gebhart M, Di Cosimo S, de Azambuja E, Demeestere I. Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial. Journal Of Clinical Oncology 2022, 40: 12084-12084. DOI: 10.1200/jco.2022.40.16_suppl.12084.Peer-Reviewed Original ResearchAnti-HER2 therapyAnti-Mullerian hormoneAMH levelsAnti-HER2 agentsOvarian reserveWeekly paclitaxelPrimary ovarian insufficiencyWeek 2NeoALTTO trialPremenopausal womenHER2-positive early breast cancerBaseline AMH levelsSubsequent ovarian functionLower AMH levelsBiomarker analysisEarly breast cancerMedian AMH levelsTime of surgeryHER2-positive BCSystemic anticancer treatmentBreast cancer patientsFrozen serum samplesNeoadjuvant trialsOncofertility counsellingPotential gonadotoxicity
2021
Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial.
Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Rothé F, Sotiriou C. Copy number aberration analysis to predict response to neoadjuvant anti-HER2 therapy: results from the NeoALTTO phase III clinical trial. Clinical Cancer Research 2021, 27: clincanres.1317.2021. PMID: 34321278, DOI: 10.1158/1078-0432.ccr-21-1317.Peer-Reviewed Original ResearchConceptsPathologic complete responseNeoALTTO trialCopy number aberrationsBreast cancerHER2-positive early-stage breast cancerEstrogen receptor-positive subgroupNeoadjuvant anti-HER2 therapyEarly-stage breast cancerHER2-positive breast cancerPhase III clinical trialsAnti-HER2 therapyAnti-HER2 agentsPredictors of responseReceptor-positive subgroupNumber aberration analysisCopy number levelsWarrants further investigationHeterogeneity of responseComplete responseSurvival outcomesWhole cohortClinical trialsImmune processesPatientsSignificant association
2017
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial
Fumagalli D, Venet D, Ignatiadis M, Azim HA, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C. RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncology 2017, 3: 227-234. PMID: 27684533, PMCID: PMC5374044, DOI: 10.1001/jamaoncol.2016.3824.Peer-Reviewed Original ResearchEvent-free survivalAnti-HER2 therapyAnti-HER2 agentsErbB2/HER2Genomic grade indexCombination armTreatment armsGene signatureBreast cancerHER2-positive early-stage breast cancerNeoadjuvant anti-HER2 therapyPathologic complete response rateHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Candidate predictive markersCycles of fluorouracilDual HER2 blockadeImmune gene signaturesComplete response rateGrowth factor receptor 2Positive breast cancerLong-term outcomesRandomized clinical trialsHigh PCR
2012
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M, Team O. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet 2012, 379: 633-640. PMID: 22257673, PMCID: PMC5705192, DOI: 10.1016/s0140-6736(11)61847-3.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantDiarrheaDrug Administration ScheduleFemaleHumansInfusions, IntravenousLapatinibLiverMiddle AgedNeoadjuvant TherapyPaclitaxelQuinazolinesReceptor, ErbB-2TrastuzumabTreatment OutcomeConceptsPathological complete responseBreast cancerHER2-positive early breast cancerHER2-positive primary breast cancerAnti-HER2 monoclonal antibody trastuzumabHER2-positive breast cancerHER2-overexpressing breast cancerTyrosine kinase inhibitor lapatinibGrade 3 diarrheaLiver enzyme alterationsAnti-HER2 agentsAnti-HER2 therapyPhase 3 studyPhase 3 trialEarly breast cancerPrimary breast cancerSingle-agent therapySynergistic antitumour activityMajor cardiac dysfunctionKinase inhibitor lapatinibMonoclonal antibody trastuzumabAdjuvant chemotherapyNeoadjuvant phaseNeoadjuvant settingOral lapatinib
2011
P4-03-04: Identification of Molecular Targets for Cancer-Initiating Cells Using a Triple-Negative Breast Cancer Mouse Model.
Kai K, Iwamoto T, Pusztai L, Hortobagyi G, Saya H, Ueno N. P4-03-04: Identification of Molecular Targets for Cancer-Initiating Cells Using a Triple-Negative Breast Cancer Mouse Model. Cancer Research 2011, 71: p4-03-04-p4-03-04. DOI: 10.1158/0008-5472.sabcs11-p4-03-04.Peer-Reviewed Original ResearchTriple-negative breast cancerTumor-initiating activityCancer-initiating cellsHuman triple-negative breast cancerTNBC mouse modelMammary fat padHigh tumor-initiating activityMouse modelTumor cellsRecipient miceClinical aggressivenessBreast cancerMouse mammary epithelial cellsFat padTriple-negative breast cancer mouse modelBackground Triple-negative breast cancerBreast cancer mouse modelAnti-HER2 agentsMouse mammary fat padMolecular profileBreast cancer subtypesCancer mouse modelEndothelin-A receptorExpression levelsCancer initiating cells
2005
Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.
Esteva FJ, Pusztai L. Optimizing outcomes in HER2-positive breast cancer: the molecular rationale. Oncology 2005, 19: 5-16. PMID: 19364051.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsCell ProliferationCombined Modality TherapyDisease ProgressionDrug Resistance, NeoplasmErbB ReceptorsFemaleGenetic TherapyHSP90 Heat-Shock ProteinsHumansProtein Kinase InhibitorsReceptor, ErbB-2TrastuzumabConceptsAnti-HER2 therapyHER2-positive breast cancerBreast cancerEpidermal growth factor receptor HER2Small molecule tyrosine kinase inhibitorsGrowth factor receptor HER2Common chemotherapy regimensSuppression of HER2Anti-HER2 agentsHER2-positive cancersStandard of careOverexpression of HER2Use of therapiesTyrosine kinase inhibitorsHER2 blockersChemotherapy regimensSequential regimensRandomized trialsMaximum antitumor effectMechanisms of resistanceClinical trialsOptimizing outcomesAntitumor effectsReceptor HER2HER2 activity